Liver Function Test among Patients with Non-Alcoholic Fatty Liver Disease


  • Ahlam K. Mohammed Department of Biochemistry, College of Medicine, University of Basrah, Iraq
  • Salman K. Ajlan Department of Biochemistry, College of Medicine, University of Basrah, Iraq
  • Aseel R. Issa Department of Surgery, College of Medicine, University of Basrah, Iraq


Non-alcoholic fatty liver disease, aspartate aminotransferase, Alanine transaminase, Total Serum Bilirubin


NAFLD is one of the most common liver diseases worldwide, and is associated with obesity, type 2 diabetes, high blood pressure, and body fat imbalance. The disease is classified into two main types: simple fatty liver, which does not usually lead to liver damage, and non-alcoholic steatohepatitis (NASH), which can progress to scarring (fibrosis) of the liver or even liver failure. The effect of non-alcoholic fatty liver disease on liver function levels and the relationship between them. The study included 75 patients with NAFLD, 34 males and 41 females, 18-75 years of age, they are diagnosed by ultrasound at GIT & hepatobiliary, and other group as control group included 81 apparently healthy subjucts 46 males and 35 females, 18-75 years of age. Physiological measurements include waist circumference, height, weight, BP, Approximately 5 ml of venous blood samples were obtained from both control individuals and patients with NAFLD after 10-12 hour overnight fasting by using sterile disposable syringes for the assessment of total serum bilirubin, unconjugated and conjugated bilirubin, Aspartate aminotransferase (AST), and alanine aminotransferase (ALT). The results shows a significant increase in the levels of AST and ALT (P<0.01) in patients group, while there is non-significant change (P>0.05) in each of total TSB, direct bilirubin, indirect bilirubin, total protein, albumin and globulin. The results were based on the determination of unconjugated and conjugated bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT). The serum of people who have non-alcoholic fatty liver disease (NAFLD) may contain elevated levels of AST and ALT. Because bilirubin, albumin, globulin, and total protein do not have any effect on non-alcoholic fatty liver disease (NAFLD), it is reasonable to assume that their levels do not change in people with NAFLD.


Download data is not yet available.


Y. Pang, C. Kartsonaki, I. Turnbull, Y. Guo, Y. Chen, and ..., “Adiposity in relation to risks of fatty liver, cirrhosis and liver cancer: a prospective study of 0.5 million Chinese adults,” Sci Rep, 2019, [Online]. Available:

A. A. Mansour, “Metabolic Syndrome Among Adults Population Single Center Experance In Basrah,” The Medical Journal of Basrah University, 2005, [Online]. Available:

J. B. Dixon, P. S. Bhathal, and P. E. O’brien, “Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese,” Gastroenterology, 2001, [Online]. Available:

J. M. Clark, F. L. Brancati, and A. M. Diehl, “The prevalence and etiology of elevated aminotransferase levels in the United States,” Official journal of the American …, 2003, [Online]. Available:

J. A. Del Campo, R. Gallego-Durán, P. Gallego, and ..., “Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD),” International journal of …, 2018, [Online]. Available:

M. Basaranoglu and ..., “Nonalcoholic fatty liver disease: clinical features and pathogenesis,” Gastroenterology & …, 2006, [Online]. Available:

E. M. Brunt and D. G. Tiniakos, “Histopathology of nonalcoholic fatty liver disease,” World journal of gastroenterology: WJG, 2010, [Online]. Available:

A. E. Feldstein, N. W. Werneburg, A. Canbay, and ..., “Free fatty acids promote hepatic lipotoxicity by stimulating TNF‐α expression via a lysosomal pathway,” …, 2004, doi: 10.1002/hep.20283.

N. Chalasani, Z. Younossi, J. E. Lavine, M. Charlton, and ..., “The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases,” Hepatology, 2018, doi: 10.1002/hep.29367.

D. L. Young-Hyman, “National institute of diabetes and digestive and kidney diseases,” Encyclopedia of behavioral medicine, 2020, doi: 10.1007/978-3-030-39903-0_764.

G. Targher, L. Bertolini, R. Padovani, S. Rodella, and ..., “Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients,” Diabetes …, 2007, [Online]. Available:

M. J. Armstrong, L. A. Adams, A. Canbay, and W. K. Syn, “Extrahepatic complications of nonalcoholic fatty liver disease,” Hepatology, 2014, doi: 10.1002/hep.26717.

S. Treeprasertsuk, E. Björnsson, F. Enders, and ..., “NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients,” World journal of …, 2013, [Online]. Available:

A. Katz, S. S. Nambi, K. Mather, A. D. Baron, and ..., “Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans,” The Journal of …, 2000, [Online]. Available:

D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, and ..., “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, 1985, doi: 10.1007/bf00280883.

V. Ratziu, S. Bellentani, H. Cortez-Pinto, and ..., “A position statement on NAFLD/NASH based on the EASL 2009 special conference,” Journal of …, 2010, [Online]. Available:

V. D. Thong and B. T. H. Quynh, “Correlation of serum transaminase levels with liver fibrosis assessed by transient elastography in vietnamese patients with nonalcoholic fatty liver disease,” Int J Gen Med, 2021, doi: 10.2147/IJGM.S309311.

D. Sanyal, P. Mukherjee, M. Raychaudhuri, and ..., “Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes,” Indian journal of …, 2015, [Online]. Available:

T. Novakovic, M. Mekic, L. Smilic, T. Smilic, and ..., “Anthropometric and biochemical characteristics of patients with nonalcoholic fatty liver diagnosed by non-invasive diagnostic methods,” Medical …, 2014, [Online]. Available:

A. Zakeri and S. Karamat-Panah, “Prevalence of non-alcoholic fatty liver disease and its risk factors in patients referred to Ardabil city hospital during 2015-2016,” Int J Community Med Pub Health, 2018, [Online]. Available:

M. Swain, P. Nath, P. K. Parida, J. Narayan, and ..., “Biochemical profile of nonalcoholic fatty liver disease patients in eastern India with histopathological correlation,” Indian Journal of Clinical …, 2017, doi: 10.1007/s12291-016-0612-7.

J. K. Dyson, Q. M. Anstee, and S. McPherson, “Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging,” Frontline Gastroenterol, 2014, [Online]. Available:

Y. Chang, S. Ryu, E. Sung, and Y. Jang, “Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease,” Clin Chem, 2007, [Online]. Available:

N. C. Leite, G. F. Salles, A. L. E. Araujo, and ..., “Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus,” Liver …, 2009, doi: 10.1111/j.1478-3231.2008.01718.x.

P. Nath, R. Kumar, B. Mallick, S. Das, A. Anand, and ..., “Effect of nonalcoholic fatty liver disease (NAFLD) on COVID-19: a single-center study of 3983 patients with review of literature,” Cureus, 2022, [Online]. Available:

W. Dunn and J. B. Schwimmer, “The Role of the Microbiome in Nonalcoholic Fatty Liver Disease,” Nat Rev Gastroenterol Hepatol, vol. 15, no. 5, pp. 278–288, 2018.

P. Ge et al., “Albumin binding function: the potential earliest indicator for liver function damage,” … Research and Practice, 2016, [Online]. Available:

L. Özgönenel, S. Turan, T. Şahin, and A. N. Değer, “The utility of noninvasive liver fibrosis markers in patients with nonalcoholic fatty liver disease,” Eur J Gastroenterol Hepatol, vol. 30, no. 2, pp. 218–221, 2018.

N. Alaaeldin, M. Shaker, and A. Osman, “Non-alcoholic fatty liver disease and the relationship between type 2 diabetes and aminotransferase levels,” Diabetes Res Clin Pract, vol. 97, no. 2, pp. 241–247, 2012.

M. S. Kwak, D. Kim, G. E. Chung, S. J. Kang, and ..., “Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease,” Clinical and …, 2012, [Online]. Available:

C. Lipina and H. S. Hundal, “Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance,” Diabetologia, 2011, doi: 10.1007/s00125-011-2127-3.

J. Du Plessis, J. Van Pelt, H. Korf, C. Mathieu, and ..., “Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease,” Gastroenterology, 2015, [Online]. Available:




How to Cite

Mohammed, A. K., Ajlan, S. K., & Issa, A. R. (2024). Liver Function Test among Patients with Non-Alcoholic Fatty Liver Disease. INTERNATIONAL JOURNAL OF HEALTH SYSTEMS AND MEDICAL SCIENCES, 3(2), 35–44. Retrieved from